Aberdeen scientists to explore African seas for drug discoveries
Research could lead to new treatments for cancer and MRSA
A team will travel to Ghana next month to search the waters for unique marine organisms that could be used to develop new medicines.
The scientists hope to find previously undiscovered species of corals, sponges and sea squirts. They will examine these organisms for new molecules, bacteria and fungi, which could be used in the creation of new treatments for diseases prevalent in Africa – including tuberculosis and parasitic diseases such as malaria.
Professor Marcel Jaspars, director of the Marine Biodiscovery Centre, said: ‘Drug discovery work in West Africa has historically focused on land, investigating how molecules in plants can be used in the development of new medicines.
‘Our project marks the first time waters off the coast of West Africa have been explored to assess the diversity of marine organisms available in this area, and the potential they could harbour in the treatment of a number of diseases.’
Jaspars said the team would collect samples at low tide around the Gulf of Guinea and Guinea Basin, where they believe they will find new species.
The Aberdeen scientists will work with the University of Ghana during the trip, which marks the beginning of a three-year collaborative project between the two institutions.
The £1.6m Marine Biodiscovery Centre – which brings together chemists and biologists to work on the development of new pharmaceuticals from organisms from the depths of the world’s oceans – opened in June. It is one of only three in Europe dedicated to the exploration of the natural resources from our seas.
The project is funded by the Leverhulme Trust and co-ordinated by the Royal Society.
You may also like
Trending Articles
You may also like
Drug Delivery
Bio-Sourcing and Zerion Pharma secure Eurostars funding to develop HER2 oral monoclonal antibody
The pair have been awarded a €1.3m Eurostars grant to develop an oral formulation of the anti-HER2 monoclonal antibody trastuzumab for breast cancer, combining Bio-Sourcing’s BioMilk platform with Zerion’s Dispersome technology to advance the candidate through preclinical development
Research & Development
FairJourney Bio launches cryo-EM services to support antibody discovery and biologics design
The new offering at the company's San Diego laboratories provides high-resolution structural insights to accelerate antibody discovery, selection and optimisation across the biologics R&D pipeline
Research & Development
Studies on HIV and TB reveal tradeoffs for both viruses and immune system in race to survive
Research teams have identified mechanisms by which HIV can evade lenacapavir, at the cost of the virus's reproduction and how the immune system can use bacteria to protect against infection — until TB evolved to take advantage
Research & Development
Enara Bio expands Boehringer Ingelheim partnership as DARKFOX programme moves toward the clinic
Enara Bio has entered 2026 with renewed momentum after Boehringer Ingelheim licensed additional Dark Antigen targets under their oncology collaboration. The company is also continuing to expand its EDAPT discovery platform
Research & Development
Early stage clinical trials highlight the convergence of novel therapeutics and enabling technologies
Early stage clinical development is increasingly being shaped by advances in drug discovery and the technologies and manufacturing strategies that enable the safe, precise and scalable delivery of new therapies